1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Syncom Formulation (India) Ltd.

Syncom Formulation (India) Ltd.

21.16
INR
-0.92
(-4.17%)
0.94EPS
15.14P/E
13.40BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2.71
2.22
2.36
2.19
2.14
2.3
2.39
3.07
2.67
2.4
2.76
4.87
5.12
5.48
Basic EPS, GAAP
0.17
0.12
0.13
0.13
0.12
0.14
0.17
0.37
0.24
0.22
0.27
0.53
0.81
0.94
Free Cash Flow per Basic Share
0.12
- -
0.25
0.11
-0.11
0.05
0.05
-0.03
0.06
-0.11
-0.15
0.14
0.49
- -
Dividend per Share
0.03
0.02
0.02
0.02
0.03
- -
- -
- -
- -
0.03
- -
- -
- -
- -
Book Value per Share
1.22
1.28
1.35
1.46
1.56
1.7
1.87
2.37
2.58
2.72
3.07
3.64
4.41
- -
Tangible Book Value per Share
1.22
1.28
1.35
1.46
1.56
1.7
1.86
2.37
2.58
2.72
3.06
3.64
4.41
- -
Basic Weighted Avg Shares
559
781
781
819
721
792
838
781
817
929
940
940
940
908
Sales/Revenue/Turnover
1,513
1,734
1,839
1,795
1,540
1,820
2,001
2,393
2,178
2,225
2,592
4,574
4,817
4,978
Operating Margin (%)
8.7
8.54
7.65
7.4
5.18
4.31
6.36
14.63
7.93
7.39
9.71
11.84
16.13
16.29
Depreciation Expense
31
34
30
31
37
40
41
40
39
45
47
52
65
67
Net Income, GAAP
93
98
104
107
86
111
143
292
198
201
253
494
764
855
Effective Tax Rate (%)
33.1
37.6
35.68
33.41
28.03
12.51
17.56
28.33
24.39
24.47
25.44
24.54
24.41
24.36
Profit Margin (%)
6.16
5.63
5.63
5.94
5.61
6.09
7.12
12.19
9.09
9.02
9.76
10.81
15.87
17.18
Working Capital
365
469
285
302
387
455
582
931
615
685
1,683
2,106
2,266
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
952
1,002
1,056
1,141
1,219
1,326
1,457
1,876
2,222
2,560
2,881
3,422
4,150
- -
Return on Invested Capital (%)
9.58
9.22
8.96
7.66
4.46
4.98
7.23
12.63
4.94
4.02
5.36
11.55
15.39
- -
Return on Capital (%)
10.15
9.66
9.56
9.13
6.77
8.18
10.17
14.75
7.99
7.26
8.16
14.13
20.16
- -
Return on Common Equity (%)
10.19
9.99
10.06
9.69
7.33
8.71
10.24
17.51
9.66
8.39
9.3
15.69
20.19
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
15
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
940
940
940
Market Capitalization
13,404
9,682
13,404

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
3,304
- -
Cash, Cash Equivalents & STI
- -
1,126
- -
Accounts Receivable, Net
- -
1,105
- -
Inventories
- -
629
- -
Total Current Liabilities
- -
1,037
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
15
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.85%
17.25%
21.29%
Free Cash Flow
-110.8%
-111.27%
244.37%
Net Income, GAAP
29.08%
29.06%
54.62%
Sales/Revenue/Turnover
12.26%
18.29%
5.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
873
1,023
1,275
1,489
4,574
2026
1,169
1,217
1,151
1,354
4,817
2027
1,255
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.11
0.16
0.14
0.19
0.53
2026
0.17
0.18
0.23
0.27
0.81
2027
0.26
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rahul Vijay Bankda
Full Time Employees
2,790
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Syncom House Indore MP India 452018
IPO Date
Jan 24, 1994
Website
syncomformulations.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Syncom Formulations (India) Limited manufactures, markets, and exports pharmaceutical formulations in various dosage forms including tablets, capsules, liquids orals, liquid vials and ampoule injections, dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gels, ORS, and jellies; it offers specialized products in antibiotics/antiinfectives, anthelmintics, antimalarials, cardiac, dermatological, gastroenterological, gynecological, ophthalmological, orthopedic, and pediatric categories; under the Cratus brand, it provides life care, Evolve reproductive medicine and women's care, and right nutrition products; the company also engages in commodity trading and property renting. Incorporated in 1988 and headquartered in Indore, Madhya Pradesh, India, with manufacturing facilities at Pithampur and a registered office in Mumbai, Syncom Formulations operates WHO-GMP and ISO 9001-2015 certified plants, serving domestic markets through its Cratus division and exporting to over 25 countries with more than 400 registered products. In November 2025, the company acquired a commercial property in Mumbai's Andheri-Kurla Road area for Rs 51.70 crore from HDFC Bank Ltd, representing a material expansion of its fixed assets; additionally, in 2024, shareholders approved the re-appointment of Chairman and Whole-Time Director Kedarmal Bankda effective May 2025 and Managing Director Vijay Bankda effective November 2024, each for two-year terms.